Online inquiry

IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4733MR)

This product GTTS-WQ4733MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL21 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001207006.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 59067
UniProt ID Q9HBE4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4733MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ5334MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ13037MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ11911MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ5216MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ9848MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ9232MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ368MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ10408MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2439821
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW